The Company has two active stock plans, the 2009 Stock Incentive Plan (the “2009 Plan”) and the 2009 Employee Stock Purchase Plan (the “2009 ESPP”) that have been amended and approved by shareholders from time to time.

•The 2009 Plan allows for grants of stock options, stock appreciation rights, performance shares, performance stock units, restricted stock units (“RSUs”), restricted stock awards (“RSAs”), performance-based stock units (“PSUs”) and other awards (collectively, “awards”). All awards deduct one share from the 2009 Plan shares available for issuance for each share granted. Awards granted under the 2009 Plan contain vesting provisions mostly ranging from three to four years. To the extent awards granted under the 2009 Plan terminate, expire, or lapse for any reason, or are settled in cash, shares subject to such awards will again be available for grant.

•The 2009 ESPP allows eligible employees to purchase a limited number of shares of the Company’s common stock at no less than 85% of the fair market value of a share of common stock at prescribed purchase intervals during an offering period. Each offering period is comprised of a series of one or more successive and/or overlapping purchase intervals and has a maximum term of 27 months.

The Company granted to its employees 0.7 million, 0.5 million and 0.5 million shares of full value awards from the 2009 Plan during fiscal 2024, 2023 and 2022, respectively. Full value awards include RSUs, MSUs, and PSUs.

MSUs provide the rights to acquire a number of shares of common stock for no cash consideration based upon achievement of specified levels of market conditions. The requisite measurement period for these MSUs is also the vesting period, which is generally three years. MSUs granted in 2020 measured the relative performance of the total stockholders’ return of the Company against that of a selected benchmarked group of companies. The Company granted no MSUs in fiscal 2024, 2023 and 2022.

PSUs provide for the rights to acquire a number of shares of common stock for no cash consideration based upon the achievement of specified revenue or profitability objectives during the year. The requisite performance period of these PSUs is approximately three years from the date of grant. The Company granted 95,953, 85,554, and 52,078 PSUs in fiscal 2024, 2023, and 2022, respectively.

The rights to purchase common stock granted under the 2009 ESPP are intended to be treated as either (i) purchase rights granted under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Internal Revenue Code (the “423(b) Plan”), or (ii) purchase rights granted under an employee stock purchase plan that is not subject to the terms and conditions of Section 423(b) of the Internal Revenue Code (the “Non-423(b) Plan”). The Company will retain the discretion to grant purchase rights under either the 423(b) Plan or the Non-423(b) Plan. During fiscal 2024, 2023 and 2022, the Company issued 173,000, 154,000, and 109,000 shares, respectively, under the 2009 ESPP to its employees. The weighted-average fair value for purchase rights granted in fiscal 2024 under the 2009 ESPP was $32.28 per share.

Stock-based compensation costs are based on the fair values on the date of grant for awards under the 2009 Plan, and on the date of enrollment for grants under the 2009 ESPP. The fair values of stock awards (such as RSUs, PSUs and RSAs) are estimated based on their intrinsic values. The fair values of MSUs are estimated using a Monte Carlo simulation. The fair values of stock options and grants under the 2009 ESPP are estimated using the Black-Scholes option-pricing model. The fair values of all such stock-based grants are generally amortized on a straight-line basis over the vesting period of the grants.

The Company estimates potential forfeitures of stock grants and adjusts compensation cost recorded accordingly. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are

expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of stock-based compensation expense to be recognized in future periods.


	Year Ended
	December 28, 2024		December 30, 2023		December 31, 2022
Cost of revenues	$	1,678	$	906	$	1,152
Research and development	40,393		35,491		32,860
Selling, general and administrative	19,431		11,812		26,498
	61,503		48,208		60,510
Income tax benefit	(8,557)		(6,230)		(5,980)
Total	$	52,946	$	41,978	$	54,530

The Company recorded $0.6 million and $0.6 million of stock-based compensation charges during fiscal 2024 and 2023 respectively, in connection with the modification of certain equity awards. The modifications were pursuant to employee terminations. There were no other significant modifications made to any stock grants during fiscal 2024, 2023 or 2022.

The Company had approximately $104.3 million of total unrecognized compensation cost related to equity grants as of December 28, 2024 that is expected to be recognized over a weighted-average period of approximately 2.0 years. There were no significant stock-based compensation costs capitalized into assets in any of the periods presented.


	Year Ended
Employee Stock Purchase Plan	December 28, 2024		December 30, 2023		December 31, 2022
Expected volatility	45	%	40	%	44	%
Risk-free interest rate %	4.39	%	5.47	%	3.18	%
Expected term (in months)	9		9		9
Dividend yield	—		—		—


Stock Options	Shares (000s)	Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value (000s)
Outstanding at December 30, 2023	94	$	39.03	2.12	$	8,790
Exercised	76	$	37.88		$	6,063
Outstanding at December 28, 2024	18	$	43.82	1.08	$	1,534
Vested at December 28, 2024 and expected to vest	18	$	43.82	1.08	$	1,534
Exercisable at December 28, 2024	18	$	43.82	1.08	$	1,534


RSAs and RSUs	Shares (000s)	Weighted- Average Grant Date Fair Value		Weighted-Average Remaining Vesting Term (In Years)	Aggregate Intrinsic Value (000s)
Outstanding at December 30, 2023	824	$	138.95
Granted	605	$	125.19
Vested or issued	(385)	$	135.90
Cancelled or forfeited	(76)	$	129.69
Outstanding at December 28, 2024	968	$	132.26	1.22	$	123,685

Outstanding at December 28, 2024 and expected to vest	887	$	132.62	1.22	$	113,354


PSUs and MSUs	Shares (000s)	Weighted- Average Grant Date Fair Value		Weighted-Average Remaining Vesting Term (In Years)	Aggregate Intrinsic Value (000s)
Outstanding at December 30, 2023	245	$	164.62
Granted	116	$	138.22
Vested or issued	(55)	$	165.27
Cancelled or forfeited	(71)	$	143.51
Outstanding at December 28, 2024	235	$	165.73	1.23	$	30,069

Outstanding at December 28, 2024 and expected to vest	50	$	139.69	1.23	$	6,401


	Year Ended
	December 28, 2024		December 30, 2023		December 31, 2022
Per grant of RSAs and RSUs	$	125.19	$	137.11	$	144.40
Per grant of PSUs and MSUs	$	138.22	$	188.45	$	160.97


	Year Ended
	December 28, 2024		December 30, 2023		December 31, 2022
Intrinsic value of stock options exercised	$	6,063	$	2,162	$	—
Intrinsic value of RSUs that vested	$	49,008	$	61,371	$	57,621
Grant date fair value of RSUs that vested	$	52,371	$	53,088	$	41,610
Intrinsic value of PSUs and MSUs that vested	$	7,202	$	5,163	$	—
Grant date fair value of PSUs and MSUs that vested	$	9,067	$	3,037	$	—